Quarterly ResultMay 13, 2026, 05:07 PM
Petros Pharmaceuticals Q1 Net Loss $0.99M; EPS $(0.03); Going Concern Warning
AI Summary
Petros Pharmaceuticals reported a net loss of $0.99 million for the first quarter of 2026, significantly reduced from $2.26 million in the prior year, with a basic and diluted EPS of $(0.03). The company's cash and cash equivalents stood at $4.35 million as of March 31, 2026. Management issued a going concern warning, stating that the company lacks sufficient liquidity for the next 12 months, and is exploring various financing strategies while focusing on developing its Rx-to-OTC switch technology platform after discontinuing previous operations.
Key Highlights
- Reported Q1 2026 net loss of $987,036, down from $2,260,022 in Q1 2025.
- Basic and diluted EPS from continuing operations was $(0.03) for Q1 2026.
- Cash and cash equivalents totaled $4.35 million as of March 31, 2026.
- Company issued a going concern warning due to insufficient liquidity for the next 12 months.
- Accumulated deficit reached $112.3 million as of March 31, 2026.
- Net cash used in operating activities was $784,272 for Q1 2026.
- Company is transforming to focus on Rx-to-OTC switch technology platform.
- Discontinued sales of Stendra and assigned assets of Metuchen and subsidiaries in 2025.